Stablepharma key facts
as of Oct 2026- Developer of a thermostability technology designed to improve the stability and accessibility of temperature-sensitive vaccines.
- Stablepharma is valued at approximately $72.2M as of Oct 2026 (last reported valuation).
- It has raised $10.5M; the latest was Grant ($2.6M) in Feb 2025.
- Notable investors include Innovate UK, European Innovation Council, SFC Capital, Ascension, Ascension Ventures — 10 tracked in total.
- Status: Privately Held (backing).
Stablepharma's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·Watch Stablepharma: the Monday email on marks, rounds and moves
Stablepharma funding rounds
No funding rounds for Stablepharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Stablepharma valuation
Stablepharma's last reported valuation was $72.2 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
Stablepharma investors
10 investors are on record for Stablepharma, including Innovate UK, European Innovation Council, SFC Capital and Ascension. By type, the record holds 3 venture capital firms, 1 hedge fund and 1 fund of funds.
About Stablepharma
Developer of a thermostability technology designed to improve the stability and accessibility of temperature-sensitive vaccines. The company offers advanced formulation and preservation methods, enabling vaccine manufacturers, academic institutions, and global health organizations to improve distribution efficiency and reduce dependence on cold storage.
- Sector
- Healthcare
- HQ
- Bath, United Kingdom
- Founded
- 2012
- Employees
- 24
- Website
- stablepharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.